CA2445049A1 - Rapidly cleavable sumo fusion protein expression system for difficult to express proteins - Google Patents
Rapidly cleavable sumo fusion protein expression system for difficult to express proteins Download PDFInfo
- Publication number
- CA2445049A1 CA2445049A1 CA002445049A CA2445049A CA2445049A1 CA 2445049 A1 CA2445049 A1 CA 2445049A1 CA 002445049 A CA002445049 A CA 002445049A CA 2445049 A CA2445049 A CA 2445049A CA 2445049 A1 CA2445049 A1 CA 2445049A1
- Authority
- CA
- Canada
- Prior art keywords
- amino acid
- recombinant
- protease
- poly
- ulp1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000014509 gene expression Effects 0.000 title claims description 69
- 108020001507 fusion proteins Proteins 0.000 title claims description 50
- 102000037865 fusion proteins Human genes 0.000 title claims description 49
- 108090000623 proteins and genes Proteins 0.000 title description 47
- 102000004169 proteins and genes Human genes 0.000 title description 43
- 150000001413 amino acids Chemical class 0.000 claims description 88
- 239000012634 fragment Substances 0.000 claims description 58
- 108091005804 Peptidases Proteins 0.000 claims description 55
- 239000004365 Protease Substances 0.000 claims description 55
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 51
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 49
- 238000000746 purification Methods 0.000 claims description 48
- 238000003776 cleavage reaction Methods 0.000 claims description 44
- 230000007017 scission Effects 0.000 claims description 37
- 239000013598 vector Substances 0.000 claims description 37
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 36
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 36
- 230000002708 enhancing effect Effects 0.000 claims description 30
- 108010018628 Ulp1 protease Proteins 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 24
- 238000010367 cloning Methods 0.000 claims description 19
- 108020004414 DNA Proteins 0.000 claims description 18
- 238000003259 recombinant expression Methods 0.000 claims description 15
- 150000007523 nucleic acids Chemical group 0.000 claims description 14
- 108091008146 restriction endonucleases Proteins 0.000 claims description 14
- 239000002773 nucleotide Substances 0.000 claims description 13
- 125000003729 nucleotide group Chemical group 0.000 claims description 13
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 8
- 102000053602 DNA Human genes 0.000 claims description 6
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 6
- 102000002933 Thioredoxin Human genes 0.000 claims description 6
- 239000013612 plasmid Substances 0.000 claims description 6
- 108060008226 thioredoxin Proteins 0.000 claims description 6
- 229940094937 thioredoxin Drugs 0.000 claims description 6
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims description 5
- 229920002704 polyhistidine Polymers 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 2
- 101000684503 Homo sapiens Sentrin-specific protease 3 Proteins 0.000 claims 17
- 102100023645 Sentrin-specific protease 3 Human genes 0.000 claims 17
- 102000051619 SUMO-1 Human genes 0.000 claims 5
- 108700038981 SUMO-1 Proteins 0.000 claims 3
- 101000879203 Caenorhabditis elegans Small ubiquitin-related modifier Proteins 0.000 claims 2
- 229910021645 metal ion Inorganic materials 0.000 claims 1
- 230000004927 fusion Effects 0.000 description 27
- 108090000765 processed proteins & peptides Proteins 0.000 description 24
- 210000004027 cell Anatomy 0.000 description 19
- 241000588724 Escherichia coli Species 0.000 description 17
- 101100095557 Caenorhabditis elegans ulp-1 gene Proteins 0.000 description 14
- 108091022894 CDPdiacylglycerol-Serine O-Phosphatidyltransferase Proteins 0.000 description 12
- 101150091206 Nfkbia gene Proteins 0.000 description 12
- 239000013604 expression vector Substances 0.000 description 12
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 12
- 102000004190 Enzymes Human genes 0.000 description 11
- 108090000790 Enzymes Proteins 0.000 description 11
- 229940088598 enzyme Drugs 0.000 description 11
- 108020004707 nucleic acids Proteins 0.000 description 11
- 102000039446 nucleic acids Human genes 0.000 description 11
- 210000004899 c-terminal region Anatomy 0.000 description 9
- 102000004196 processed proteins & peptides Human genes 0.000 description 9
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 8
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 8
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 8
- 108020004999 messenger RNA Proteins 0.000 description 8
- 238000004128 high performance liquid chromatography Methods 0.000 description 7
- 238000003752 polymerase chain reaction Methods 0.000 description 7
- 108020004705 Codon Proteins 0.000 description 6
- 102000005720 Glutathione transferase Human genes 0.000 description 6
- 108010070675 Glutathione transferase Proteins 0.000 description 6
- 238000001042 affinity chromatography Methods 0.000 description 6
- 125000000539 amino acid group Chemical group 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 5
- 108091026890 Coding region Proteins 0.000 description 4
- 239000004471 Glycine Substances 0.000 description 4
- 102000035195 Peptidases Human genes 0.000 description 4
- 101150102102 SMT3 gene Proteins 0.000 description 4
- 108090000190 Thrombin Proteins 0.000 description 4
- 102000044159 Ubiquitin Human genes 0.000 description 4
- 108090000848 Ubiquitin Proteins 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 230000002950 deficient Effects 0.000 description 4
- 229960004072 thrombin Drugs 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- 101100478890 Caenorhabditis elegans smo-1 gene Proteins 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 102000012745 Immunoglobulin Subunits Human genes 0.000 description 3
- 108010079585 Immunoglobulin Subunits Proteins 0.000 description 3
- 108010052285 Membrane Proteins Proteins 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 101150096255 SUMO1 gene Proteins 0.000 description 3
- 101100408688 Schizosaccharomyces pombe (strain 972 / ATCC 24843) pmt3 gene Proteins 0.000 description 3
- 101710183280 Topoisomerase Proteins 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 230000017854 proteolysis Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 108010037870 Anthranilate Synthase Proteins 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000222122 Candida albicans Species 0.000 description 2
- 108010074860 Factor Xa Proteins 0.000 description 2
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 2
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 2
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 108010088160 Staphylococcal Protein A Proteins 0.000 description 2
- 241000723792 Tobacco etch virus Species 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- PWBJWDKDPAPGED-UHFFFAOYSA-N n'-chlorobutanediamide Chemical compound NC(=O)CCC(=O)NCl PWBJWDKDPAPGED-UHFFFAOYSA-N 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 239000013600 plasmid vector Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 2
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- 108020005098 Anticodon Proteins 0.000 description 1
- 244000105975 Antidesma platyphyllum Species 0.000 description 1
- KLKHFFMNGWULBN-VKHMYHEASA-N Asn-Gly Chemical compound NC(=O)C[C@H](N)C(=O)NCC(O)=O KLKHFFMNGWULBN-VKHMYHEASA-N 0.000 description 1
- 108700004676 Bence Jones Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108010013369 Enteropeptidase Proteins 0.000 description 1
- 102100029727 Enteropeptidase Human genes 0.000 description 1
- XZWYTXMRWQJBGX-VXBMVYAYSA-N FLAG peptide Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)CC1=CC=C(O)C=C1 XZWYTXMRWQJBGX-VXBMVYAYSA-N 0.000 description 1
- 102000013382 Gelatinases Human genes 0.000 description 1
- 108010026132 Gelatinases Proteins 0.000 description 1
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 101100408135 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) phnA gene Proteins 0.000 description 1
- 108090000783 Renin Proteins 0.000 description 1
- 102100028255 Renin Human genes 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- 108030003004 Triphosphatases Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 239000011358 absorbing material Substances 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000000779 depleting effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 235000009424 haa Nutrition 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000017730 intein-mediated protein splicing Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 229920000724 poly(L-arginine) polymer Polymers 0.000 description 1
- 229920001308 poly(aminoacid) Polymers 0.000 description 1
- 108010011110 polyarginine Proteins 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000000135 prohibitive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 101150044170 trpE gene Proteins 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/95—Fusion polypeptide containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28865601P | 2001-05-04 | 2001-05-04 | |
| US60/288,656 | 2001-05-04 | ||
| US32908001P | 2001-10-12 | 2001-10-12 | |
| US60/329,080 | 2001-10-12 | ||
| PCT/US2002/014062 WO2002090495A2 (en) | 2001-05-04 | 2002-05-06 | Rapidly cleavable sumo fusion protein expression system for difficult to express proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2445049A1 true CA2445049A1 (en) | 2002-11-14 |
Family
ID=26965151
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002445049A Abandoned CA2445049A1 (en) | 2001-05-04 | 2002-05-06 | Rapidly cleavable sumo fusion protein expression system for difficult to express proteins |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US6872551B2 (enExample) |
| EP (1) | EP1392717B1 (enExample) |
| JP (1) | JP2004532033A (enExample) |
| AT (1) | ATE490968T1 (enExample) |
| AU (1) | AU2002257243A1 (enExample) |
| CA (1) | CA2445049A1 (enExample) |
| DE (1) | DE60238532D1 (enExample) |
| WO (1) | WO2002090495A2 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103184228A (zh) * | 2011-12-29 | 2013-07-03 | 天津市国际生物医药联合研究院 | 用于可结晶成熟型SARS冠状病毒非结构蛋白12(sars-nsp12)的外源重组表达及纯化方法 |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001009292A2 (en) * | 1999-07-31 | 2001-02-08 | Board Of Regents, The University Of Texas System | Sentrin-specific human proteases senp1-3 |
| US7198924B2 (en) | 2000-12-11 | 2007-04-03 | Invitrogen Corporation | Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites |
| DE60238532D1 (de) * | 2001-05-04 | 2011-01-20 | Cornell Res Foundation Inc | Schnell spaltbares sumofusionsprotein-expressionssystem für schwer zu exprimierende proteine |
| US8535908B2 (en) * | 2002-01-04 | 2013-09-17 | Brookhaven Science Associates, Llc | Facilitating protein solubility by use of peptide extensions |
| US7060461B2 (en) * | 2002-01-07 | 2006-06-13 | Lifesensors, Inc. | Methods and compositions for protein expression and purification |
| US7220576B2 (en) * | 2002-01-07 | 2007-05-22 | Lifesensors, Inc. | Methods and compositions for protein expression and purification |
| JP2005532829A (ja) * | 2002-07-18 | 2005-11-04 | インヴィトロジェン コーポレーション | 組換え部位を含むウイルスベクター |
| WO2004063214A2 (en) * | 2003-01-08 | 2004-07-29 | Government Of The United States Of America As Represented By The Sercretary Of The Department Of Health And Human Services National Institutes Of Health | Antibodies that specifically recognize sumo-conjugated proteins |
| CA2530530A1 (en) * | 2003-06-26 | 2005-01-13 | Lifesensors, Inc. | Methods and compositions for enhanced protein expression and purification |
| WO2005014796A2 (en) | 2003-08-08 | 2005-02-17 | Invitrogen Corporation | Methods and compositions for seamless cloning of nucleic acid molecules |
| US8507277B2 (en) | 2003-10-24 | 2013-08-13 | Gencia Corporation | Nonviral vectors for delivering polynucleotides |
| US8133733B2 (en) | 2003-10-24 | 2012-03-13 | Gencia Corporation | Nonviral vectors for delivering polynucleotides to target tissues |
| WO2005056752A2 (en) | 2003-10-24 | 2005-06-23 | Gencia Corporation | Methods and compositions for delivering polynucleotides |
| US8062891B2 (en) | 2003-10-24 | 2011-11-22 | Gencia Corporation | Nonviral vectors for delivering polynucleotides to plants |
| US20090208478A1 (en) * | 2003-10-24 | 2009-08-20 | Gencia Corporation | Transducible polypeptides for modifying metabolism |
| US20090123468A1 (en) | 2003-10-24 | 2009-05-14 | Gencia Corporation | Transducible polypeptides for modifying metabolism |
| DE602004027538D1 (de) | 2003-12-01 | 2010-07-15 | Life Technologies Corp | Rekombinationsstellen enthaltende nukleinsäuremoleküle und verfahren zur verwendung davon |
| ES2306541B1 (es) * | 2004-04-16 | 2009-09-28 | Consejo Superior Investig. Cientificas | Trasplante funcional de la maquinaria de sumoilacion a escherichia coli. |
| CA2576083A1 (en) * | 2004-08-18 | 2006-02-23 | Joel Weiner | Protein production method utilizing yebf |
| US8119369B2 (en) * | 2004-12-30 | 2012-02-21 | Lifesensors, Inc. | Human SUMO-3 for enhancing protein expression |
| CA2670014A1 (en) * | 2006-11-22 | 2008-11-20 | Emory University | Production of anti-microbial peptides |
| EP2100961A1 (en) * | 2008-03-04 | 2009-09-16 | Icon Genetics GmbH | Method of protease production in plants |
| US20090280531A1 (en) * | 2008-05-06 | 2009-11-12 | Academia Sinica | Preparation of Soluble Capsid Proteins of Picornaviruses Using SUMO Fusion Technology |
| TW200951219A (en) * | 2008-05-06 | 2009-12-16 | Academia Sinica | An improved SUMO fusion protein system for effective production of native proteins |
| US8440449B2 (en) * | 2008-09-30 | 2013-05-14 | The United States Of America, As Represented By The Secretary Of Agriculture | Transformed Saccharomyces cerevisiae engineered for xylose utilization |
| US8663951B2 (en) * | 2009-01-09 | 2014-03-04 | Academia Sinica | Method of producing virus-like particles of picornavirus using a small-ubiquitin-related fusion protein expression system |
| CN102533712A (zh) * | 2009-05-12 | 2012-07-04 | 中国科学院上海生命科学研究院 | 一种固相化sumo化系统及固相化去sumo化系统 |
| CN101993495B (zh) * | 2009-08-12 | 2013-07-24 | 上海近岸科技有限公司 | 一种蛋白质混合物及其制备方法 |
| WO2013103964A1 (en) | 2012-01-06 | 2013-07-11 | Gencia Corporation | Methods and compositions for treating proteinopathies |
| WO2013188873A1 (en) | 2012-06-15 | 2013-12-19 | Gencia Corporation | Compositions and methods for enhancing immune responses |
| US20160038565A1 (en) | 2012-06-15 | 2016-02-11 | Gencia Corporation | Methods of Mitigating Side Effects of Radiation Exposure and Chemotherapy |
| AU2013326968B2 (en) | 2012-10-03 | 2019-08-08 | Agrivida, Inc. | Multiprotein expression cassettes |
| KR101911438B1 (ko) | 2012-10-31 | 2018-10-24 | 삼성전자주식회사 | 이중 특이 항원 결합 단백질 복합체 및 이중 특이 항체의 제조 방법 |
| US9707244B2 (en) | 2013-03-15 | 2017-07-18 | Gencia Corporation | Compositions and methods for treating conditions that affect epidermis |
| US9970945B2 (en) | 2013-06-07 | 2018-05-15 | Georgia State University Research Foundtion, Inc. | Compositions, methods, and assays using proteo-liposome-transfected oocytes for analyzing the structure, function, and activity of membrane proteins |
| US9447157B2 (en) | 2013-09-13 | 2016-09-20 | Augusta University Research Institute, Inc. | Nitration shielding peptides and methods of use thereof |
| WO2015049230A1 (en) | 2013-10-01 | 2015-04-09 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | An orthogonal set of tag-cleaving proteases for purification of proteins and stoichiometric protein complexes |
| US10378003B2 (en) | 2014-11-10 | 2019-08-13 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Tag removal from proteins expressed in pro- and eukaryotic hosts |
| AU2016338559B2 (en) | 2015-10-14 | 2022-11-24 | Translate Bio, Inc. | Modification of RNA-related enzymes for enhanced production |
| TWI591177B (zh) * | 2016-10-27 | 2017-07-11 | 中化合成生技股份有限公司 | 一種胰高血糖素胜肽－２（ｇｌｐ－２）類似物的製備方法 |
| US10913777B2 (en) | 2017-05-22 | 2021-02-09 | The Regents Of The University Of California | In vitro assembly of bacterial microcompartments |
| US20190070262A1 (en) | 2017-09-06 | 2019-03-07 | Yale University | Interleukin-18 variants and methods of use |
| KR20190135393A (ko) * | 2018-05-28 | 2019-12-06 | 주식회사 원진바이오테크놀로지 | 폴리유비퀴틴 스캐폴드에 결합된 생체분자들의 선형 멀티머 중합체 및 이의 용도 |
| CN109517074A (zh) * | 2018-12-04 | 2019-03-26 | 湖北大学 | 一种融合标签促进Kuma030蛋白酶可溶性表达及非亲和层析快速纯化的应用 |
| CN109628479A (zh) * | 2018-12-25 | 2019-04-16 | 天津农学院 | 一种胰高血糖素样肽-1的重组表达方法 |
| EP3906248A4 (en) * | 2019-01-04 | 2022-08-10 | Repertoire Immune Medicines, Inc. | METHODS FOR PRODUCING HIGH DIVERSITY PEPTIDE BANKS AND PROMOTING PROTEIN FOLDING |
| CN113025675B (zh) * | 2021-05-21 | 2021-08-20 | 凯莱英医药集团（天津）股份有限公司 | 多肽的制备方法 |
| EP4479088A1 (en) | 2022-02-14 | 2024-12-25 | University of Georgia Research Foundation, Inc. | Pan-pneumovirus vaccine compositions and methods of use thereof |
| CN114426586A (zh) * | 2022-02-21 | 2022-05-03 | 中国农业大学 | 一种胞外分泌表达Ulp1蛋白酶的大肠杆菌基因工程菌株及其应用 |
| CN114539425B (zh) * | 2022-02-25 | 2023-04-28 | 湖南中晟全肽生化有限公司 | 一种提高线性多肽生物表达的方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5132213A (en) * | 1986-10-02 | 1992-07-21 | Massachusetts Institute Of Technology | Method for producing proteins and polypeptides using ubiquitin fusions |
| US5643758A (en) * | 1987-03-10 | 1997-07-01 | New England Biolabs, Inc. | Production and purification of a protein fused to a binding protein |
| AU6290496A (en) * | 1995-06-27 | 1997-01-30 | Igen International, Inc. | High-level expression and efficient recovery of ubiquitin fusion proteins from escherichia coli |
| DE60238532D1 (de) * | 2001-05-04 | 2011-01-20 | Cornell Res Foundation Inc | Schnell spaltbares sumofusionsprotein-expressionssystem für schwer zu exprimierende proteine |
| US7060461B2 (en) * | 2002-01-07 | 2006-06-13 | Lifesensors, Inc. | Methods and compositions for protein expression and purification |
-
2002
- 2002-05-06 DE DE60238532T patent/DE60238532D1/de not_active Expired - Lifetime
- 2002-05-06 CA CA002445049A patent/CA2445049A1/en not_active Abandoned
- 2002-05-06 AU AU2002257243A patent/AU2002257243A1/en not_active Abandoned
- 2002-05-06 WO PCT/US2002/014062 patent/WO2002090495A2/en not_active Ceased
- 2002-05-06 JP JP2002587558A patent/JP2004532033A/ja active Pending
- 2002-05-06 AT AT02726837T patent/ATE490968T1/de not_active IP Right Cessation
- 2002-05-06 EP EP02726837A patent/EP1392717B1/en not_active Expired - Lifetime
- 2002-07-02 US US10/188,343 patent/US6872551B2/en not_active Expired - Lifetime
-
2004
- 2004-09-24 US US10/949,685 patent/US7498165B2/en not_active Expired - Fee Related
-
2008
- 2008-10-10 US US12/249,334 patent/US7910364B2/en not_active Expired - Lifetime
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103184228A (zh) * | 2011-12-29 | 2013-07-03 | 天津市国际生物医药联合研究院 | 用于可结晶成熟型SARS冠状病毒非结构蛋白12(sars-nsp12)的外源重组表达及纯化方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002090495A2 (en) | 2002-11-14 |
| WO2002090495A8 (en) | 2003-07-03 |
| US7910364B2 (en) | 2011-03-22 |
| DE60238532D1 (de) | 2011-01-20 |
| US20050069988A1 (en) | 2005-03-31 |
| US7498165B2 (en) | 2009-03-03 |
| EP1392717B1 (en) | 2010-12-08 |
| EP1392717A4 (en) | 2005-06-08 |
| US20030086918A1 (en) | 2003-05-08 |
| US20090317868A1 (en) | 2009-12-24 |
| US6872551B2 (en) | 2005-03-29 |
| AU2002257243A1 (en) | 2002-11-18 |
| EP1392717A1 (en) | 2004-03-03 |
| ATE490968T1 (de) | 2010-12-15 |
| JP2004532033A (ja) | 2004-10-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7498165B2 (en) | Rapidly cleavable SUMO fusion protein expression system for difficult to express proteins | |
| Catanzariti et al. | An efficient system for high‐level expression and easy purification of authentic recombinant proteins | |
| US5506121A (en) | Fusion peptides with binding activity for streptavidin | |
| Young et al. | Recombinant protein expression and purification: a comprehensive review of affinity tags and microbial applications | |
| US7655413B2 (en) | Methods and compositions for enhanced protein expression and purification | |
| JP4377242B2 (ja) | ビオチン化ドメインを含むタンパク質タグ、及び溶解性を増大させる方法、及び折り畳み状態を決定する方法 | |
| US20190292535A1 (en) | Nucleic acids encoding chimeric polypeptides for library screening | |
| US5935823A (en) | Totally synthetic affinity reagents | |
| JP2005516074A6 (ja) | ビオチン化ドメインを含むタンパク質タグ、及び溶解性を増大させる方法、及び折り畳み状態を決定する方法 | |
| AU2003238441A1 (en) | Protein tag comprising a biotinylation domain and method for increasing solubility and determining folding state | |
| US7220576B2 (en) | Methods and compositions for protein expression and purification | |
| CA2376062A1 (en) | Fusion proteins comprising a fragment of a chaperon polypeptide | |
| JP4749548B2 (ja) | インテイン媒介ペプチド連結 | |
| US20070275416A1 (en) | Affinity marker for purification of proteins | |
| CN101172996A (zh) | 用于多肽融合表达的连接肽及多肽融合表达方法 | |
| EP1981978B1 (en) | Affinity polypeptide for purification of recombinant proteins | |
| Bell | E. coli expression systems | |
| Kang et al. | Heterologous expression and optimized one-step separation of levansucrase via elastin-like polypeptides tagging system. | |
| US20180141972A1 (en) | Native protein purification technology | |
| CN111662388A (zh) | 一种蛋白质表达纯化的方法 | |
| US20050106671A1 (en) | Expression vector, host cell and method for producing fusion proteins | |
| Cole et al. | Gene expression and tagging of streptococcal proteins | |
| US20110177615A1 (en) | Protein expression | |
| HK1128727B (en) | Chimaeric fusion protein with superior chaperone and folding activities | |
| HK1128727A1 (en) | Chimaeric fusion protein with superior chaperone and folding activities |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |
Effective date: 20140506 |